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Abstract (202 words)
Alcohol use disorders (AUD) are defined by several symptom criteria, which can be 
further dissected at the genetic level. Over the past several years, our 
understanding of the genetic factors influencing alcohol use and abuse has 
progressed tremendously; hundreds of loci have now been implicated in different 
aspects of alcohol use. Previously known associations with alcohol metabolizing 
enzymes (ADH1B, ALDH2) have been definitively replicated. Additionally, novel 
associations with loci containing the genes KLB, GCKR, CRHR1 and CADM2 have 
been reported. Downstream analyses have leveraged these genetic findings to 
reveal important relationships between alcohol use behaviors and both physical and
mental health. AUD and aspects of alcohol misuse have been shown to overlap 
strongly with psychiatric disorders, whereas aspects of alcohol consumption have 
shown stronger links to metabolism. These results demonstrate that the genetic 
architecture of alcohol consumption only partially overlaps with the genetics of 
clinically defined AUD. We discuss the limitations of using quantitative measures of 
alcohol use as proxy measures for AUD, and outline how future studies will require 
careful phenotype harmonization to properly capture the genetic liability to AUD. 
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Introduction
Alcohol abuse is a global problem, constituting the seventh leading risk factor
for death and disability (1). Worldwide, over 100 million people had an alcohol use 
disorder (AUD) in 2016. Statistics from the National Survey on Drug Use and Health 
show that >85% of adults in the United States report ever having consumed 
alcohol, with >25% reporting binge drinking in the past month (2). The proportion of
adults in the United States with an AUD is estimated to be 6.2% (2). Alcohol use 
behaviors are complex, and how and why people drink is partially influenced by 
genetic factors. However, identifying the genetic factors that increase the risk for 
harmful drinking has been challenging, partially because patterns of alcohol use are
dynamic across the lifespan. The terms used to describe alcohol use and abuse are 
as diverse as the behaviors themselves. Hazardous drinking describes heavy 
drinking that places an individual at risk for future harm. Harmful drinking and 
alcohol abuse are defined as drinking that causes mental or physical damage to the 
individual. These descriptive terms were devised to identify individuals who would 
benefit from brief interventions and are assessed using screening questionnaires 
such as the Alcohol Use Disorders Identification Test (AUDIT). Alcohol dependence 
(AD) was, until recently, defined according to the DSM-IV and required the presence
of 3 or more of 7 criteria in a 12-month period. The DSM-IV made a distinction 
between alcohol abuse and dependence that was removed under DSM-V and 
replaced with ‘mild’ to ‘severe’ definitions of AUD. Genetic studies encompass the 
wide range of alcohol use phenotypes; in this review we mirror the language used in
the original studies. 
AUD can be viewed as the end point of a series of transitions (Figure 1), 
which begin with the initiation of use, continue with the escalation to hazardous 
drinking and culminate in compulsive harmful use that persists despite negative 
consequences. Genome-wide association studies (GWAS) have been instrumental 
in discovering novel genetic loci associated with multiple psychiatric conditions. In 
the field of AUD genetics, studies have mostly focused on either levels of 
consumption or AUD diagnosis. Recent GWAS have now begun to identify hundreds 
of genome-wide significant variants, and provide evidence that the components of 
alcohol use behavior have a distinct genetic architecture.
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In this review, we provide an overview of recent molecular genetic findings of
alcohol use behaviors from the largest GWAS performed to date. Other reviews 
have elegantly summarized findings from twin and family studies of heritability, 
linkage, candidate gene and GWAS [e.g. (3–6)], and we extend on recent reviews of 
the molecular genetics of AUD (7–9) by including additional GWAS of alcohol use 
behaviors that identify genome-wide significant hits (P-value < 5 x 10-8). In addition,
we discuss the application of polygenic methods, which provide mounting evidence 
that alcohol use and misuse are partially distinct. Finally, we delineate future 
directions to investigate the different etiologic sources that underlie the life course 
of alcohol use behaviors.
Design strategies for enhancing AUD genetic discovery
For decades, candidate gene studies were used to determine the contribution
of specific genes that increase risk for AUD. Candidate gene studies tended to focus
on genes that influenced pharmacokinetic and pharmacodynamic (e.g. 
dopaminergic, glutamatergic and opioid signaling systems) factors. Larger genetic 
studies have generally not replicated the findings from candidate gene studies (10).
One exception to this are the genes encoding ethanol metabolizing enzymes, 
particularly alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), 
which have repeatedly been shown to have the largest impact on alcohol 
consumption and risk for AUD (7).
As study designs have evolved to incorporate GWAS, researchers have been 
able to scan the whole genome without any hypotheses about the underlying 
biology of alcohol use behaviors. Initial efforts focused on collecting clinically-
defined cases of AUD, but these ascertainment strategies could not amass the large
sample sizes required for GWAS (11). Accordingly, multi-ethnic and clinically-
defined samples have been combined through the Psychiatric Genomic Consortium 
of Substance Use Disorders (PGC-SUD) working group. The efforts of the PGC-SUD 
have led to a trans-ancestral meta-analysis consisting of almost 15,000 AD cases 
and almost 38,000 controls from 28 independent cohorts (12), identifying a single 
locus (ADH1B), which was robustly associated with AD. More recently, using 
information from electronic health records to infer AUD status, a GWAS of 274,424 
multi-ethnic individuals from the Million Veterans Program (MVP) cohort identified 
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10 loci associated with AUD (including ADH1B) (18). Kranzler et al (18) showed that 
alcohol consumption and AUD were genetically correlated but distinct, thus allowing
them to adjust for consumption in the AUD GWAS and for AUD in the GWAS of 
consumption. 
In parallel with these efforts, which have focused on clinical diagnoses, other 
GWAS have incorporated continuous measures of alcohol use. These include self-
reported weekly alcohol intake or the scores from screening questionnaires such as 
the AUDIT (13). The AUDIT can be decomposed to provide a measure of alcohol use 
from the first 3 questions (AUDIT-C) and misuse from questions 4-10 (AUDIT-P). 
These quantitative measures are available in large population-based cohorts such 
as the UK Biobank (UKB), MVP and 23andMe. The GWAS meta-analysis of AUDIT 
identified 10 associated risk loci (14). Large consortia were also formed to collate 
quantitative measures of alcohol use, including AlcGen (15) and the GWAS & 
Sequencing Consortium of Alcohol and Nicotine Use (GSCAN). GSCAN have recently
identified nearly 100 loci associated with alcohol consumption (17). The MVP study
(18) also examined alcohol consumption, allowing for an explicit comparison 
between AUD and consumption in a single population; of the 18 loci detected in that
study, 5 were common to both AUD diagnosis and alcohol consumption. 
As the prior two paragraphs make clear, population based cohorts have 
provided larger sample sizes, which are critical for obtaining adequate power for 
GWAS. Their use can come at the cost of missing more severe alcohol use 
phenotypes. For example, the frequency of AUD in the UKB is lower than the 
population average [7% (19)], indicating that certain population studies may be 
underpowered to detect genetic effects specific to dependence (20). The frequency 
of AUD in the MVP, on the contrary, was much higher [20%, (18)]. Despite these 
limitations, population based cohorts provide a cost-effective strategy for obtaining 
very large samples, compared to traditional study designs that require obtaining a 
diagnosis from clinically trained staff. 
Recent discoveries on the molecular genetics of alcohol use behaviors
Table 1 summarizes the most recent GWAS of alcohol use behaviors (N = 
16); Figure 2 provides an overview of the chronology of these studies. Figure 3 
shows that the list of genes identified by these studies is highly heterogeneous. 
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These data suggest incomplete genetic overlap between measures of alcohol use 
behaviors (Figure 4), though ascertainment bias and limited power (see Figure 5) 
are likely to be additional contributing factors. 
The 4q23 region, which contains the genes for several alcohol metabolizing 
enzymes, has been associated with multiple alcohol use behaviors. This association 
is one of the most consistently replicated findings in the field of psychiatric 
genetics, although the effects are clearly ancestry-specific (7). There appear to be 
multiple signals in this region, including ADH1C (17, 18, 21–24), ADH4 (18), ADH5
(21, 23) and the METAP1/EIF4E region (21–23). The GSCAN consortium recently 
showed that there are at least 13 independent signals with minor allele frequencies 
over 0.001 at 4q23 (21). Intriguingly, several of those loci are also strongly 
implicated in non-psychiatric, somatic traits (25).
Beyond the alcohol metabolizing genes, the region containing the genes 
beta-klotho (KLB) and the Fibroblast growth factor 21 (FGF21) has been robustly 
associated with alcohol consumption. The AlcGen consortium was the first to show 
that the A allele of rs11940694 (Figure 2), located in the intron of KLB, was 
associated with reduced alcohol consumption (15). This finding has since been 
replicated (Table 1) - the same SNP was associated with alcohol consumption (17, 
18, 22, 23) and alcohol misuse (22). Beta-klotho is a transmembrane protein that 
acts as a cofactor for the circulating hormone fibroblast growth factor 21 (FGF21) 
by facilitating its binding to FGF receptors (FGFR). Interestingly the FGF21 gene, 
which is located on chromosome 19, was also associated with AUDIT scores at the 
gene-level in humans (22). Beta-klotho is primarily expressed in the liver, adipose 
tissue and pancreas (26), and recent studies have shown that it regulates brain 
specific functions related to alcohol consumption in mice. For example, mice lacking
brain expressed Klb showed increased ethanol preference (15). Furthermore, FGF21
was found to suppress ethanol consumption in wild-type mice but had no effect on 
mice lacking Klb in the brain. Previous studies have shown that FGF21 and KLB are 
involved in sweet and alcohol preference in mice (27), and a recent study in 
humans found increased FGF21 expression in blood after binge drinking (28). These 
findings suggest that KLB and FGF21 act as part of a brain-liver endocrine axis that 
regulates alcohol consumption. Future studies could explore the effects of 
analogues of FGF21 on alcohol consumption, which are currently being tested in 
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clinical trials for the treatment of type 2 diabetes and obesity (29). Although KLB 
and FGF21 seem to be promising avenues for translational research, it is worth 
noting that while SNPs in KLB are associated with alcohol consumption, they have 
not yet shown any association with AUD (12, 18). This implies that this system 
might only be relevant for the regulation of normative consumption, although 
studies of larger AUD populations may yet reveal a role for these loci in AUD. 
Furthermore, although the locus probably impacts KLB, rs11940694 was found to be
an expression quantitative trait locus (eQTL) for RFC1 gene expression in the 
cerebellum and hemisphere (22, 23).
Another well-replicated locus associated with both alcohol consumption and 
AUD is the region containing the glucokinase receptor (GCKR) gene, whose product 
is a regulatory protein that is produced by hepatocytes and is involved in the 
cellular trafficking of glucokinase. A non-synonymous SNP in GCKR, rs1260326, was 
robustly associated with alcohol consumption in the MVP, UKB and 23andMe 
samples (Table 1). Intriguingly, rs1260326 has also been previously associated 
with multiple metabolic traits, including diabetes, obesity and liver disease (30, 31). 
Given that alcohol consumption is strongly associated with both metabolic and lipid 
profiles (e.g. 25, 32, 33), it is not clear whether the association with rs1260326 
pinpoints a pleiotropic process central to metabolic traits, or whether alcohol 
causally impacts glucose metabolism and lipid levels, in part via GCKR. A recent 
study characterized the effects of alcohol in neural cell cultures derived from 
induced pluripotent stem cells (iPSCs) and found that genes down-regulated upon 
alcohol exposure were involved in cholesterol homeostasis in the brain (34). These 
findings could suggest that AUD has both psychiatric and metabolic components, a 
theme that has also been suggested for other psychiatric disorders, such as 
anorexia nervosa (35). Additional evidence supporting this provocative hypothesis is
the fact that several genes associated with alcohol use and dependence involve 
brain-endocrine-metabolic mechanisms. KLB is part of a brain-liver feedback loop, 
acetaldehyde modulates a number of ethanol effects in the brain, and enrichment 
analyses of alcohol-associated genes found glutamatergic enrichment not only in 
the brain but also in glucose and carbohydrate processing pathways (21). The 
ability to process caloric alcoholic beverages may be linked to individual differences
in alcohol consumption.
7
In general, the ‘candidate genes’ for AUD that were examined in smaller 
cohorts have not been replicated by larger and better powered GWAS (10). One 
exception is the corticotropin releasing hormone receptor 1 (CRHR1), a candidate 
gene extensively studied in humans and rodents before the advent of large-scale 
GWAS studies (10). CRHR1 is central to the cortisol stress response as part of the 
hypothalamic-pituitary-axis. Extensive preclinical literature has shown that CRHR1 
is associated with relapse to drug taking in mice [e.g. (36, 37)] and there is some 
evidence that variation in CRHR1 modulates the role of psychological stress on 
alcohol intake (e.g. 38, 39). Encouragingly, the genomic region surrounding CRHR1 
has been associated with alcohol consumption and misuse in several recent GWAS 
studies (21, 22, 40). However, CRHR1 is located in an inversion polymorphism of 
roughly 900kb that is common in Europeans and induces extensive LD spanning 
many genes (41), including CRHR1 and MAPT (22). MAPT encodes the protein tau, is
involved in Parkinson’s and Alzheimer's disease. Further work is therefore required 
to determine which variant(s) are causal, as the inversion in this region complicates 
the ability of GWAS to fully address this question. 
Recent GWAS have identified several regions containing a set of genes that 
have pleiotropic effects on many psychiatric disorders and related traits; these 
genes may be tagging a latent factor (“p-factor”) (42). For example, the largest 
GWAS of alcohol and smoking, which used over 1 million individuals, performed a 
multivariate GWAS approach to show that 150 loci were associated with multiple 
substance use phenotypes; variation at PDE4B and CUL3 were associated with both 
smoking (initiation, cessation, quantity) and drinks per week. Similarly, CADM2 has 
been recently associated with alcohol and cannabis use (21, 23, 43). CADM2 is a 
cell adhesion molecule (CAM) that influences brain wiring and appears to have a 
role in multiple neuropsychiatric disorders (44). There is now mounting evidence 
from independent GWAS showing an association between common genetic variants 
at CADM2 and risky or impulsive behaviors including risk tolerance, automobile 
speeding propensity, number of sexual partners (45), sensation seeking and drug 
experimentation (46), cannabis initiation (47), and obesity and body mass index
(48–50). CADM2 has also been associated with cognitive phenotypes, including 
educational attainment (51, 52). We therefore hypothesize that genetic variation at 
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CADM2 may underlie a latent personality trait or risk factor that predisposes 
individuals to engage in risky actions (i.e. drinking behaviors). 
Despite the success of GWAS of alcohol use (Figure 4) the mechanisms by 
which these newly identified genetic associations exert their effects are largely 
unknown. More importantly, alcohol consumption and misuse (core traits associated
with development of AUD) appear to have distinct genetic architectures (Table 1, 
Figure 3). Ever-larger studies, particularly those extending mere alcohol 
consumption phenotypes, are required to find the genetic variants that contribute 
towards the transition from normative alcohol use to misuse, and development of 
AUD.
Polygenic methods generate hypotheses to test across alcohol use 
behaviors
One successful application of GWAS has been their use for assigning 
polygenic risk scores (PRS), which provide estimates of an individual’s genetic risk 
of developing a given disorder. Reassuringly, PRS for alcohol use behaviors predict 
equivalent phenotypes in independent cohorts [e.g. alcohol consumption (53), AD
(12), AUD symptoms (54)]. Johnson et al (2019) recently identified that, compared 
to PRS for alcohol consumption (AUDIT-C), PRS for alcohol misuse (AUDIT-P) were 
superior predictors of a range of alcohol-related phenotypes, particularly those 
pertaining to the domains of misuse and dependence. These findings further 
illustrate that alcohol consumption alone may not be a good proxy for AUD. 
PRS can also be used to test specific hypotheses; for example, PRS can be 
used to measure how environmental, demographic, and genetic factors interact 
with one another. Are there developmental windows where the effects of alcohol 
use and misuse are more invasive? Can we identify biomarkers that would inform 
the transition from normative alcohol use to excessive use and dependence? For 
instance, the alcohol metabolizing genetic effects on alcohol use appeared to be 
more influential in later years of college than in earlier years (55, 56), revealing that
the nature and magnitude of genetic effects vary across development. 
It is worth noting important limitations of PRS analyses. First, polygenic 
prediction is influenced by the ancestry of the population studied. For example, PRS 
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for AUD generated in an African American (AA) cohort explained more of the 
variance in AUD than PRS derived from a much larger cohort of European Americans
(12). This illustrates that the prediction from one population to another does not 
perform well (e.g. PRS based on European Americans but used to predict in AA)
(57). Second, the method of ascertainment may bias the results. As an example, 
PRS for DSM-IV AD derived from a population based sample predicted increased risk
for AD in other population samples but did not associate with AUD symptoms in a 
clinically ascertained sample (54). Third, the variance explained by PRS is still low, 
and hence PRS have limited clinical application. For example, in the largest study of 
alcohol consumption (21), the alcohol consumption PRS accounted for only ~2.5% 
of the variance in alcohol use in two independent datasets. Recent work suggested 
that predictions may improve by incorporating functional genomic information. For 
example, McCartney et al (58) showed that, compared to conventional PRS, risk 
scores that took into account DNA methylation were better predictors of alcohol 
consumption (12.5% vs PRS 0.7%; but see (59)). Nonetheless, the way in which 
such methods can be used for prevention or treatments of AUD has yet to be 
established. Lastly, it remains to be determined the nature of these associations. 
Mendelian randomization analyses can serve to further understand and explore the 
correlations between alcohol use behaviors and comorbid traits (see 
Supplemental 1).
Alcohol consumption and misuse show a distinct genetic architecture
Before the era of large-scale genomic research, twin and family-based studies
identified a high degree of genetic overlap between the genetic risk for AUD and 
psychopathology by modeling correlations among family members (e.g. (60)). With 
the recent development of linkage disequilibrium score regression (LDSC), it is now 
possible to estimate the genetic correlations between specific alcohol use behaviors
(Figure 1, Figure 4) and a plethora of psychiatric, health and educational 
outcomes using GWAS summary statistics. Most notably, the genetic overlap 
between alcohol consumption and AD was positive but relatively modest (rg = 0.38-
0.52, 12, 18), suggesting that, although the use of alcohol is necessary to develop 
AD, some of the genetic liability is specific to either levels of consumption or AD.
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Another consistent finding from genetic correlation analyses has been that 
alcohol consumption and AUD show distinct patterns of genetic overlap with disease
traits (Figure 4). Counterintuitively, alcohol consumption tends to correlate with 
desirable attributes including educational attainment and is negatively genetically 
correlated with coronary heart disease, type 2 diabetes and BMI (18, 21–23). These 
genetic correlations are unlike those observed when analyzing alcohol dependent 
individuals: AD was negatively genetically correlated with educational attainment
(18) and positively genetically correlated with other psychiatric diseases, including 
major depressive disorder (MDD), bipolar disorder, schizophrenia and attention-
deficit/hyperactivity disorder (ADHD, 12, 18). Importantly, alcohol consumption 
(AUDIT-C) and misuse (AUDIT-P or AUD) measured in the same population (UKB or 
MVP) showed distinct patterns of genetic association with psychopathology and 
health outcomes (18, 22). This set of findings emphasize the importance of deep 
phenotyping and demonstrates that alcohol consumption and problematic drinking 
have distinct genetic influences. 
Ascertainment bias may explain some of the paradoxical genetic correlations 
associated with alcohol consumption (61). Population based cohorts, such as UKB 
and 23andMe, are based on voluntary participation and tend to attract individuals 
with higher education levels and socioeconomic status than the general population 
and, crucially, lower levels of problem drinking. In contrast, ascertainment in the 
PGC and MVP cohorts (12, 18) was based on DSM-IV AD diagnosis and ICD 
(International Classification of Diseases) codes for AUD, respectively. Collider bias 
(the biased estimation of the causal effect of an exposure on an outcome) has been 
proposed to underlie some of the genetic correlations between alcohol consumption
and BMI (62); however, BMI has been consistently negatively correlated with alcohol
use in several subsequent studies (18, 21, 22, 63). Furthermore, it is also possible 
that the genetic overlap between AD and aspects of alcohol consumption are 
dependent on the specific patterns of drinking. For example, Polimanti et al (64) 
identified a positive genetic correlation between AD and alcohol drinking quantity (rg 
= 0.75), but not frequency. 
Limitations and future directions
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Prior to the availability of large population studies and collaborative consortia
efforts, few genes were reliably associated with AUD. The use of intermediate traits 
or endophenotypes (such as alcohol consumption as an intermediate phenotype for 
AUD) has become increasingly common and hundreds of new loci have now been 
associated with alcohol use behaviors. Using intermediate phenotypes also 
facilitates translational research; we can mimic aspects of human alcohol use using 
animal models, including alcohol consumption, novelty response, impulsivity, 
withdrawal and sensitivity (e.g. 65, 66). Animal models provide an opportunity to 
evaluate the role of newly identified genes (Table 1) at the molecular, cellular and 
circuit level. We may also be able to perform human genetic studies of specific 
components of AUD such as DSM-IV AD criterion count (67) and alcohol withdrawal
(68). To date these traits have only been studied in smaller samples but this 
approach will be invaluable as sample sizes increase. 
Another challenge for AUD genetics is that AUD is a dynamic phenotype, 
even more so than other psychiatric conditions, and therefore may necessitate yet 
larger sample sizes. Ever-larger studies, particularly those extending mere alcohol 
consumption phenotypes, are required to find the genetic variants that contribute 
towards the transition from normative alcohol use to misuse, and development of 
AUD. Furthermore, genetic risk unfolds across development, particularly during 
adolescence, when drug experimentation is more prominent and when the brain is 
most vulnerable to the deleterious effects of alcohol (69). The Adolescent Brain 
Cognitive Development (ABCD), with neuroimaging, genotyping and extensive 
longitudinal phenotypic information including alcohol use behaviors (70), offers new
avenues for research, namely to understand how genetic risk interacts with the 
environment across critical developmental windows. Population biobanks aligning 
genotype data from thousands of individuals to electronic health records are also 
promising emerging platforms to accelerate AUD genetic research (71).
Despite these caveats, the GWAS described in Table 1 have already vastly 
expanded our understanding of the genetic architecture of alcohol use behaviors. It 
is evident that alcohol use behaviors, like all complex traits, are highly polygenic
(11). The proportion of variance explained by genetic variants on GWAS chips (SNP-
heritability) ranges from 4 to 13% (Figure 4). It is possible that a significant portion
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of the heritability can be explained by SNPs not tagged by GWAS chips, including 
rare variants (46). For instance, a recent study showed that rare variants explained 
1-2% of phenotypic variance and 11-18% of total SNP heritability of substance use 
phenotypes (72). Nonetheless, rare variants are often not analyzed when 
calculating SNP heritability, which can lead to an underestimate of polygenic 
effects, as well as missing biologically relevant contributions for post-GWAS 
analyses (73). Equally important is the need to include other sources of -omics data 
when interpreting genetic findings, and the need to increase population diversity 
(see Supplemental 2). Therefore, a multifaceted approach targeting both rare and 
common variation, including functional data, and assembling much larger datasets 
for meta-analyses (particularly for alcohol misuse and clinical phenotypes) in 
ethnically diverse populations, is critical for identifying the key genes and pathways 
important in AUD.
Conclusion
AUD is a complex, heterogeneous disorder encompassing a variety of 
behavioral, psychological, and physiological traits with a complex longitudinal 
structure, thus posing an enormous challenge for genetic analysis. Instead, AUD can
be fractionated into dimensions or symptoms. Several recent GWAS have used this 
approach, and it is now common to study quantitative measures, including alcohol 
consumption and aspects of disordered drinking, in large population samples. As a 
result, GWAS of alcohol use, misuse and AUD are now beginning to uncover genetic 
signals that have the potential to be further analyzed at the molecular, cellular, and 
circuit level in cellular and animal model systems. Findings from polygenic 
prediction and genetic correlation analyses, which are major trends in psychiatric 
genetics, have demonstrated that alcohol use behaviors share a common genetic 
basis with numerous psychiatric, educational and health outcomes. Unsurprisingly, 
even though studying alcohol consumption has shown some utility, it is apparent 
that this phenotype cannot be used as a proxy for AUD. We anticipate that big 
datasets, including those from electronic health records, will revolutionize the field 
in the years to come.
13
Acknowledgements and Disclosures
The authors declare no conflict of interest.
Funding
SSR was supported by the Frontiers of Innovation Scholars Program (#3-P3029), the
Interdisciplinary Research Fellowship in NeuroAIDS (MH081482), a pilot award from
the NIH (DA037844) and the 2018 NARSAD Young Investigator Grant (#27676). SSR
and  AAP  were  supported  by  funds  from the  California  Tobacco-Related  Disease
Research Program (TRDRP; #28IR-0070 and T29KT-0526). AAP was supported by
NIH grants AA026281 and P50DA037844. TKC was supported by a Wellcome Trust
(Wellcome  Trust  Strategic  Award  “STratifying  Resilience  and  Depression
Longitudinally” (STRADL) Reference 104036/Z/14/Z).
14
References
1. Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A,
et al. (2018): The global burden of disease attributable to alcohol and drug 
use in 195 countries and territories, 1990–2016: a systematic analysis for the 
Global Burden of Disease Study 2016. The Lancet Psychiatry. 5: 987–1012.
2. Substance Abuse and Mental Health Services Administration (2017): Key 
substance use and mental health indicators in the United States: Results 
from the 2016 National Survey on Drug Use and Health (HHS Publication No. 
SMA 17-5044, NSDUH Series H-52). Rockville, MD: Center for Behavioral 
Health Statistics and Quality, Substance Abuse and Mental Health Services 
Administration.
3. Tawa EA, Hall SD, Lohoff FW (2016): Overview of the Genetics of Alcohol Use 
Disorder. Alcohol Alcohol. 51: 507–514.
4. Hart AB, Kranzler HR (2015): Alcohol Dependence Genetics: Lessons Learned 
From Genome-Wide Association Studies (GWAS) and Post-GWAS Analyses. 
Alcohol Clin Exp Res. 39: 1312–1327.
5. Hancock DB, Markunas CA, Bierut LJ, Johnson EO (2018): Human Genetics of 
Addiction: New Insights and Future Directions. Current Psychiatry Reports. 
20: 8.
6. Agrawal A, Verweij KJH, Gillespie NA, Heath AC, Lessov-Schlaggar CN, Martin NG, 
et al. (2012): The genetics of addiction-a translational perspective. Transl 
Psychiatry. 2: e140.
7. Edenberg HJ, McClintick JN (2018): Alcohol Dehydrogenases, Aldehyde 
Dehydrogenases, and Alcohol Use Disorders: A Critical Review. Alcohol Clin 
Exp Res. 42: 2281–2297.
15
8. Edenberg HJ, Gelernter J, Agrawal A (2019): Genetics of Alcoholism. Curr 
Psychiatry Rep. 21: 26.
9. Deak JD, Miller AP, Gizer IR (2018): Genetics of alcohol use disorder: a review. 
Curr Opin Psychol. 27: 56–61.
10. Olfson E, Bierut LJ (2012): Convergence of genome-wide association and 
candidate gene studies for alcoholism. Alcohol Clin Exp Res. 36: 2086–2094.
11. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, Yang J (2017): 
10 Years of GWAS Discovery: Biology, Function, and Translation. Am J Hum 
Genet. 101: 5–22.
12. Walters RK, Polimanti R, Johnson EC, McClintick JN, Adams MJ, Adkins AE, et al. 
(2018): Transancestral GWAS of alcohol dependence reveals common genetic
underpinnings with psychiatric disorders. Nature Neuroscience. 21: 1656–
1669.
13. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M (1993): 
Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO 
Collaborative Project on Early Detection of Persons with Harmful Alcohol 
Consumption--II. Addiction. 88: 791–804.
14. Sanchez-Roige S, Palmer AA, Fontanillas P, Elson SL, 23andMe Research Team, 
the Substance Use Disorder Working Group of the Psychiatric Genomics 
Consortium, Adams MJ, et al. (2019): Genome-Wide Association Study Meta-
Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two 
Population-Based Cohorts. Am J Psychiatry. 176: 107–118.
15. Schumann G, Liu C, O’Reilly P, Gao H, Song P, Xu B, et al. (2016): KLB is 
associated with alcohol drinking, and its gene product β-Klotho is necessary 
16
for FGF21 regulation of alcohol preference. Proc Natl Acad Sci USA. 113: 
14372–14377.
16. Schumann G, Liu C, O’Reilly P, Gao H, Song P, Xu B, et al. (2016): KLB is 
associated with alcohol drinking, and its gene product β-Klotho is necessary 
for FGF21 regulation of alcohol preference. Proc Natl Acad Sci USA. 113: 
14372–14377.
17. Evangelou E, Gao H, Chu C, Ntritsos G, Blakeley P, Butts AR, et al. (2018): 
Genome-wide association and functional studies identify 46 novel loci for 
alcohol consumption and suggest common genetic mechanisms with 
neuropsychiatric disorders. preprint, Genetics. doi: 10.1101/453332.
18. Kranzler HR, Zhou H, Kember RL, Vickers Smith R, Justice AC, Damrauer S, et al. 
(2019): Genome-wide association study of alcohol consumption and use 
disorder in 274,424 individuals from multiple populations. Nat Commun. 10: 
1499.
19. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. (2015): 
Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National 
Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 
72: 757–766.
20. Davis KAS, Coleman JRI, Adams M, Allen N, Breen G, Cullen B, et al. (2018): 
Mental health in UK Biobank: development, implementation and results from 
an online questionnaire completed by 157 366 participants. BJPsych Open. 4: 
83–90.
21. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. (2019): Association 
studies of up to 1.2 million individuals yield new insights into the genetic 
etiology of tobacco and alcohol use. Nat Genet. 51: 237–244.
17
22. Sanchez-Roige S, Palmer AA, Fontanillas P, Elson SL, 23andMe Research Team, 
the Substance Use Disorder Working Group of the Psychiatric Genomics 
Consortium, Adams MJ, et al. (2019): Genome-Wide Association Study Meta-
Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two 
Population-Based Cohorts. Am J Psychiatry. 176: 107–118.
23. Clarke T-K, Adams MJ, Davies G, Howard DM, Hall LS, Padmanabhan S, et al. 
(2017): Genome-wide association study of alcohol consumption and genetic 
overlap with other health-related traits in UK Biobank (N=112 117). Mol 
Psychiatry. 22: 1376–1384.
24. Sanchez-Roige S, Fontanillas P, Elson SL, 23andMe Research Team, Gray JC, de 
Wit H, et al. (2019): Genome-wide association study of alcohol use disorder 
identification test (AUDIT) scores in 20 328 research participants of European 
ancestry. Addict Biol. 24: 121–131.
25. Horwitz T, Lam K, Chen Y, Xia Y, Liu C (2019): A decade in psychiatric GWAS 
research. Mol Psychiatry. 24: 378–389.
26. Ito S, Kinoshita S, Shiraishi N, Nakagawa S, Sekine S, Fujimori T, Nabeshima YI 
(2000): Molecular cloning and expression analyses of mouse betaklotho, 
which encodes a novel Klotho family protein. Mech Dev. 98: 115–119.
27. Talukdar S, Owen BM, Song P, Hernandez G, Zhang Y, Zhou Y, et al. (2016): 
FGF21 Regulates Sweet and Alcohol Preference. Cell Metab. 23: 344–349.
28. Søberg S, Andersen ES, Dalsgaard NB, Jarlhelt I, Hansen NL, Hoffmann N, et al. 
(2018): FGF21, a liver hormone that inhibits alcohol intake in mice, increases 
in human circulation after acute alcohol ingestion and sustained binge 
drinking at Oktoberfest. Mol Metab. 11: 96–103.
18
29. Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, et al. (2016): A Long-
Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves 
Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. Cell Metab.
23: 427–440.
30. Raimondo A, Rees MG, Gloyn AL (2015): Glucokinase regulatory protein: 
complexity at the crossroads of triglyceride and glucose metabolism. Curr 
Opin Lipidol. 26: 88–95.
31. Rasheed H, Stamp LK, Dalbeth N, Merriman TR (2017): Interaction of the GCKR 
and A1CF loci with alcohol consumption to influence the risk of gout. Arthritis 
Res Ther. 19: 161.
32. Ridker PM, Pare G, Parker A, Zee RYL, Danik JS, Buring JE, et al. (2008): Loci 
related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and 
GCKR associate with plasma C-reactive protein: the Women’s Genome Health
Study. Am J Hum Genet. 82: 1185–1192.
33. Jamalpour S, Zain SM, Mosavat M, Mohamed Z, Omar SZ (2018): A case-control 
study and meta-analysis confirm glucokinase regulatory gene rs780094 is a 
risk factor for gestational diabetes mellitus. Gene. 650: 34–40.
34. Jensen KP, Lieberman R, Kranzler HR, Gelernter J, Clinton K, Covault J (2019): 
Alcohol-responsive genes identified in human iPSC-derived neural cultures. 
Transl Psychiatry. 9: 96.
35. Duncan L, Yilmaz Z, Gaspar H, Walters R, Goldstein J, Anttila V, et al. (2017): 
Significant Locus and Metabolic Genetic Correlations Revealed in Genome-
Wide Association Study of Anorexia Nervosa. Am J Psychiatry. 174: 850–858.
36. Volkow ND, Koob GF, McLellan AT (2016): Neurobiologic Advances from the 
Brain Disease Model of Addiction. N Engl J Med. 374: 363–371.
19
37. Koob GF (2014): Neurocircuitry of alcohol addiction: synthesis from animal 
models. Handb Clin Neurol. 125: 33–54.
38. Clarke T-K, Schumann G (2009): Gene-environment interactions resulting in risk 
alcohol drinking behaviour are mediated by CRF and CRF1. Pharmacol 
Biochem Behav. 93: 230–236.
39. Treutlein J, Kissling C, Frank J, Wiemann S, Dong L, Depner M, et al. (2006): 
Genetic association of the human corticotropin releasing hormone receptor 1 
(CRHR1) with binge drinking and alcohol intake patterns in two independent 
samples. Mol Psychiatry. 11: 594–602.
40. Gelernter J, Sun N, Polimanti R, Pietrzak R, Levey DF, Lu Q, et al. (2019): 
Genomewide Association Study of Maximum Habitual Alcohol Intake in 
>140,000 US European- and African-American Veterans Yields Novel Risk 
Loci. Biological Psychiatry. S0006322319311564.
41. Stefansson H, Helgason A, Thorleifsson G, Steinthorsdottir V, Masson G, Barnard
J, et al. (2005): A common inversion under selection in Europeans. Nat Genet.
37: 129–137.
42. Selzam S, Coleman JRI, Caspi A, Moffitt TE, Plomin R (2018): A polygenic p factor
for major psychiatric disorders. Translational Psychiatry. 8: 205.
43. Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, et al. 
(2018): GWAS of lifetime cannabis use reveals new risk loci, genetic overlap 
with psychiatric traits, and a causal influence of schizophrenia. Nat Neurosci. 
21: 1161–1170.
44. Sakurai T (2017): The role of cell adhesion molecules in brain wiring and 
neuropsychiatric disorders. Mol Cell Neurosci. 81: 4–11.
20
45. Karlsson Linnér R, Biroli P, Kong E, Meddens SFW, Wedow R, Fontana MA, et al. 
(2019): Genome-wide association analyses of risk tolerance and risky 
behaviors in over 1 million individuals identify hundreds of loci and shared 
genetic influences. Nat Genet. 51: 245–257.
46. Sanchez-Roige S, Fontanillas P, Elson SL, Gray JC, de Wit H, MacKillop J, Palmer 
AA (2019): Genome-Wide Association Studies of Impulsive Personality Traits 
(BIS-11 and UPPS-P) and Drug Experimentation in up to 22,861 Adult 
Research Participants Identify Loci in the CACNA1I and CADM2 genes. J 
Neurosci. 39: 2562–2572.
47. Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, et al. 
(2018): GWAS of lifetime cannabis use reveals new risk loci, genetic overlap 
with psychiatric traits, and a causal influence of schizophrenia. Nat Neurosci. 
21: 1161–1170.
48. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. (2015): Genetic 
studies of body mass index yield new insights for obesity biology. Nature. 
518: 197–206.
49. Akiyama M, Okada Y, Kanai M, Takahashi A, Momozawa Y, Ikeda M, et al. (2017):
Genome-wide association study identifies 112 new loci for body mass index in
the Japanese population. Nat Genet. 49: 1458–1467.
50. Graff M, Scott RA, Justice AE, Young KL, Feitosa MF, Barata L, et al. (2017): 
Genome-wide physical activity interactions in adiposity - A meta-analysis of 
200,452 adults. PLoS Genet. 13: e1006528.
51. Okbay A, Beauchamp JP, Fontana MA, Lee JJ, Pers TH, Rietveld CA, et al. (2016): 
Genome-wide association study identifies 74 loci associated with educational 
attainment. Nature. 533: 539–542.
21
52. Davies G, Marioni RE, Liewald DC, Hill WD, Hagenaars SP, Harris SE, et al. 
(2016): Genome-wide association study of cognitive functions and 
educational attainment in UK Biobank (N=112 151). Molecular Psychiatry. 21:
758–767.
53. Marees AT, Hammerschlag AR, Bastarache L, de Kluiver H, Vorspan F, van den 
Brink W, et al. (2018): Exploring the role of low-frequency and rare exonic 
variants in alcohol and tobacco use. Drug Alcohol Depend. 188: 94–101.
54. Savage JE, Salvatore JE, Aliev F, Edwards AC, Hickman M, Kendler KS, et al. 
(2018): Polygenic Risk Score Prediction of Alcohol Dependence Symptoms 
Across Population-Based and Clinically Ascertained Samples. Alcohol Clin Exp
Res. 42: 520–530.
55. Thomas NS, Adkins A, Aliev F, Edwards AC, Webb BT, Tiarsmith EC, et al. (2018):
Alcohol Metabolizing Polygenic Risk for Alcohol Consumption in European 
American College Students. J Stud Alcohol Drugs. 79: 627–634.
56. Olfson E, Edenberg HJ, Nurnberger J, Agrawal A, Bucholz KK, Almasy LA, et al. 
(2014): An ADH1B variant and peer drinking in progression to adolescent 
drinking milestones: evidence of a gene-by-environment interaction. Alcohol 
Clin Exp Res. 38: 2541–2549.
57. Martin AR, Gignoux CR, Walters RK, Wojcik GL, Neale BM, Gravel S, et al. (2017):
Human Demographic History Impacts Genetic Risk Prediction across Diverse 
Populations. Am J Hum Genet. 100: 635–649.
58. McCartney DL, Hillary RF, Stevenson AJ, Ritchie SJ, Walker RM, Zhang Q, et al. 
(2018): Epigenetic prediction of complex traits and death. Genome Biol. 19: 
136.
22
59. Salvatore JE, Savage JE, Barr P, Wolen AR, Aliev F, Vuoksimaa E, et al. (2018): 
Incorporating Functional Genomic Information to Enhance Polygenic Signal 
and Identify Variants Involved in Gene-by-Environment Interaction for Young 
Adult Alcohol Problems. Alcohol Clin Exp Res. 42: 413–423.
60. Kendler KS, Prescott CA, Myers J, Neale MC (2003): The structure of genetic and 
environmental risk factors for common psychiatric and substance use 
disorders in men and women. Arch Gen Psychiatry. 60: 929–937.
61. Adams M, Hill WD, Howard DM, Davis KAS, Deary IJ, Hotopf M, McIntosh AM 
(2018): Factors associated with sharing email information and mental health 
survey participation in two large population cohorts. preprint, Genetics. doi: 
10.1101/471433.
62. Holmes MV, Davey Smith G (2019): Problems in interpreting and using GWAS of 
conditional phenotypes illustrated by “alcohol GWAS.” Mol Psychiatry. 24: 
167–168.
63. Clarke T-K, McIntosh AM (2018): Response to “Problems in interpreting and 
using GWAS of conditional phenotypes illustrated by alcohol GWAS.” preprint,
Genetics. doi: 10.1101/290965.
64. Polimanti R, Peterson RE, Ong J-S, MacGregor S, Edwards AC, Clarke T-K, et al. 
(2019): Evidence of causal effect of major depression on alcohol dependence:
findings from the psychiatric genomics consortium. Psychol Med. 1–9.
65. Foroud T, Phillips TJ (2012): Assessing the genetic risk for alcohol use disorders. 
Alcohol Res. 34: 266–272.
66. Foroud T, Edenberg HJ, Crabbe JC (2010): Genetic research: who is at risk for 
alcoholism. Alcohol Res Health. 33: 64–75.
23
67. Lai D, Wetherill L, Bertelsen S, Carey CE, Kamarajan C, Kapoor M, et al. (2019): 
Genome-wide association studies of alcohol dependence, DSM-IV criterion 
count and individual criteria. Genes Brain Behav. 18: e12579.
68. Smith AH, Ovesen PL, Skeldal S, Yeo S, Jensen KP, Olsen D, et al. (2018): Risk 
Locus Identification Ties Alcohol Withdrawal Symptoms to SORCS2. Alcohol 
Clin Exp Re. 42: 2337–2348.
69. Dick DM, Barr PB, Cho SB, Cooke ME, Kuo SI-C, Lewis TJ, et al. (2018): Post-
GWAS in Psychiatric Genetics: A Developmental Perspective on the “Other” 
Next Steps. Genes Brain Behav. 17: e12447.
70. Volkow ND, Koob GF, Croyle RT, Bianchi DW, Gordon JA, Koroshetz WJ, et al. 
(2018): The conception of the ABCD study: From substance use to a broad 
NIH collaboration. Developmental Cognitive Neuroscience. 32: 4–7.
71. Sanchez-Roige S, Palmer AA (2019): Electronic Health Records Are the Next 
Frontier for the Genetics of Substance Use Disorders. Trends Genet. 35: 317–
318.
72. Brazel DM, Jiang Y, Hughey JM, Turcot V, Zhan X, Gong J, et al. (2018): Exome 
Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic 
Architecture of Rare Coding Variants in Smoking and Alcohol Use. Biol 
Psychiatry. . doi: 10.1016/j.biopsych.2018.11.024.
73. Wainschtein P, Jain DP, Yengo L, Zheng Z, TOPMed Anthropometry Working 
Group, Trans-Omics for Precision Medicine Consortium, Cupples LA, et al. 
(2019): Recovery of trait heritability from whole genome sequence data. 
preprint, Genetics. doi: 10.1101/588020.
24
FIGURE LEGENDS
Figure 1. The downward spiral of alcohol use disorders. There is an initial 
prodromal stage during which certain individuals may be at increased risk to be 
exposed to alcohol. Personality traits such as sensation seeking are thought to 
promote alcohol experimentation, and transition to a more regular use of alcohol. 
As alcohol use patterns become more frequent, and tolerance develops, individuals 
are more likely to loss control over alcohol drinking behavior; risk factors, such as 
impulsivity, are considered to promote the transition to a more harmful use of 
alcohol. Alcohol intake may then become inflexible and compulsive, leading to 
hazardous or continuous alcohol use despite the negative physical and 
psychological consequences, and ultimately stagnating into dependence. Attempts 
to quit or cut-down may become apparent; these may be followed by an aversive 
negative affective state, or withdrawal, thereby increasing the urges to use alcohol, 
precipitating relapse, and thus perpetuating the spiral of alcohol use disorders.
Figure 2. Timeline of major findings in alcohol use behaviors (alcohol use, yellow; 
alcohol sensitivity and withdrawal, light orange; alcohol misuse, orange; alcohol 
dependence and AUD, dark orange) using GWAS methods. Not all references in 
Table 1 are included in this figure. 
Figure 3. Gene-Phenotype network. Shared and specific genetic contributions at 
different stages or symptoms associated with alcohol use disorders, including 
alcohol use, indices of alcohol misuse severity (MaxDrinks, AUDIT-P), alcohol 
dependence, response to alcohol. Only SNPs in genes showing a significant (P < 10-
8) association with multiple AUD and alcohol-related traits, and available from the 
GWAS catalog at the time of this writing, are included. AUDIT, Alcohol Use Disorder 
Identification Test; AUDIT-C, Alcohol Use Disorder Identification Test items 1-3; AD, 
alcohol dependence; AUD, alcohol use disorder; UKB, UK Biobank; MVP, Million 
Veterans Program; AlcGen, Alcohol Genome-wide Association Consortium; GSCAN, 
GWAS & Sequencing Consortium of Alcohol and Nicotine use Consortium; GxE, gene
by environment interaction; GWAS, genome-wide association study. 
Figure 4. Heritability and genetic correlation estimates across alcohol use 
behaviors. Values (%) on the diagonal represent SNP-heritability estimates. Blank 
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boxes represent pairs of traits that are not significantly genetically correlated; - 
represents a pair of traits that have not been tested.
Figure 5. GWAS hits discovered as a function of sample size and alcohol use 
behaviors. AUDIT, Alcohol Use Disorder Identification Test; AUDIT-C, Alcohol Use 
Disorder Identification Test items 1-3. Interactive plot: 
http://rpubs.com/sanchezroige/475742
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TABLE LEGENDS
Table 1. List of genes associated across two or more GWAS of alcohol consumption 
and/or abuse. Studies are included if they demonstrate an association with the SNP 
denoted in the table, or with a SNP in LD (r2 > 0.6).
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TABLES
Table 1
Chromosom
e
Nearest gene SNP Alcohol
consumption
Alcohol abuse /
AUD
References
2 GCKR rs1260326 Y Y (17, 18, 21–23) 
4 KLB rs11940694 Y  (15, 17, 21–23)
4 KLB rs35538052 Y  (18, 21)
4 ADH1B rs1229984 Y Y (12, 17, 18, 21–23)
4 SLC39A8 rs13107325 Y Y  (17, 18, 21, 22)
2 LINC01833 rs1004787 Y Y  (17, 18, 21)
17 MAPT/CHRH1 rs62062288 Y Y (17, 21, 22)  
19 IZUMO/
FGF21
rs281379 Y Y  (17, 21, 22)   
16 FTO rs35538052 Y (17, 18)
4 ADH1C rs14278306
2
Y Y (17, 18)
3 CADM2 rs62250685 Y (21, 23) 
List of genes most commonly associated across GWAS of alcohol consumption and/or abuse. Studies are included if 
they demonstrate an association with the SNP denoted in the table, or with a SNP in LD (r2 > 0.6). Of note, the 
proximity of the listed SNPs to the nearest gene does not prove that the gene is causal. 
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